Today's Rundown Can adding Novo's GLP-1 to Gilead's NASH combo help hit fatty liver disease? New trial aims to find out Unlocking small data, the ‘next frontier’ in drug discovery Aurinia poaches CEO Peter Greenleaf from Cerecor [Sponsored] The Power to Pivot: Using Dedicated Onsite Resources to Adapt Recruitment Practices in a Shifting Landscape Ebola survivors' immune responses offer clues for vaccine development EuroBiotech Report—Bayer boosts U.S. research workforce, Poxel sees diabetes success and Kymab turns to Merck KGaA for next CEO FiercePharmaAsia—PD-1 royalty dispute; Takeda Latam asset sale; Chinese genomics investor in U.S. Chutes & Ladders—Shire R&D chief jumps ship to Ironwood spinout amid Takeda megamerger Featured Story | | | Friday, April 12, 2019 After announcing a small but broadly positive combo for its two biotech buyout NASH drugs yesterday, Gilead is hoping that adding a diabetes and obesity drug from Novo Nordisk can help boost its ability to knock out fat in the liver. |
|
|
| This week's sponsor is Deloitte. | | | Deloitte's 2019 Life Sciences accounting and financial reporting update
Insights on new accounting standards and more
A year of major change for life sciences companies is underway. Deloitte's latest update on life sciences financial reporting explains what accounting departments need to know to keep up in a rapidly evolving environment. Download the full report here. |
Top Stories Friday, April 12, 2019 “Ultimately, every drug discovery project starts off as a small-data project,” said Andrew Hopkins, Exscientia CEO. “And of course, that is where the commercial imperative is as well, to develop innovative medicines.” Friday, April 12, 2019 Peter Greenleaf arrives at Aurinia as it moves its drug, voclosporin, through phase 3 for lupus nephritis, a type of kidney inflammation related to lupus. Monday, April 8, 2019 Increasingly complex trials place a burden on study sites, exacerbating already-troubling recruitment and enrollment issues. Strategically placed Enrollment Assistants can ease that burden, making sites more agile and offering patients personalized attention that leads to conversion and retention. Thursday, April 11, 2019 Vaccines against the Ebola virus have been distributed amid several outbreaks. But the immune response to the virus is still not fully understood, which makes improving vaccine design a challenge. Now, scientists in France have found some clues to improving the vaccines by studying survivors from the 2014-2016 outbreak. Friday, April 12, 2019 In this week's EuroBiotech Report, Bayer is planting seeds in Kendall Square, Poxel saw its shares jump, Kymab turns to former German Merck executive, J&J Vision and Edwards spend millions on new medtech manufacturing sites in Ireland and more. Friday, April 12, 2019 Nobel laureate demands a bigger cut of Ono's Opdivo revenues; on a selloff spree, Takeda is said to be scouting bidders for its Latin American business; the Trump administration forces a Chinese genomics investor out of a U.S. health service platform; and more. Friday, April 12, 2019 Shire R&D chief jumps ship to Ironwood spinout amid Takeda megamerger; Daiichi taps new CEO as it unveils tie-up with AstraZeneca; and U.K. biotech Kymab nabs new CEO from Merck KGaA. Those moves plus more hirings, firings and retirings throughout the industry. | This week's sponsor is ExL Events. | | | |
Resources Sponsored by: Strativity Every life sciences firm talks about patient-centricity, but are you doing what it takes to deliver? Sponsored by: Data MATRIX | 3:00 AM EDT / 9:00 AM EDT / 2:00 PM EDT How to cut a study budget by 4 times? How to process CRFs 3 times faster? What made a CRO switch from a US vendor to Data MATRIX? In 45 minutes, we will dissolve myths about entering the market. Sponsored by: USDM Life Sciences The year’s biggest compliance and technology trends in life sciences. Learn about the latest trends impacting the biotech, medical device and pharmaceutical industries. Sponsored by: Eurofins Discovery Learn how to utilize allosteric modulation to maximize its full potential in drug discovery programs. Download this white paper to learn more. Sponsored by: BioAnalytix, Inc. Discussion of the potential for improving biologic drug development success through earlier, strategic application of advanced mass spectrometry, because currently, with most biologic drugs, including gene therapies, failures are realized in late-stage development, after substantial investment has been made in a candidate. Sponsored by: PointCross Life Sciences Clinical trials and biomarker data from patients when unified, harmonized, and made searchable; is a rich, reliable and controlled resource for research. This paper sets out the requirements for a Translational and Biomarker Research Workbench for scientists using the experiences from use of Xbiom™ at BioPharma. Sponsored by: Unchained Labs Download this whitepaper to learn more! Sponsored by: Patheon, part of Thermo Fisher Scientific Is Flow Chemistry right for your API Development? Sponsored by: Veradigm Real-World case study by Veradigm suggests that new medications specifically approved for the treatment of systolic heart failure may be underutilized despite being important advances in patient care. Sponsored by: Outer Edge Technology Software end of life puts you at risk for data breaches, business disruption and liability. Support for Microsoft SQL Server 2008/2008 R2 and Windows Server 2008/2008 R2 ends on July 9, 2019 and January 14, 2020, respectively. Learn how you can turn these risks into a strategic business advantage. Sponsored by: AlphaSense From new regulations to drug pricing and the latest M&A deals, learn how AI is making it easier for competitive intelligence to uncover the insights they need to stay ahead of the curve. Sponsored by: InterSystems Analytics using patients’ real-time longitudinal laboratory results, and claims data, yielded higher value information and new revenue streams for TriCore reference laboratories. Sponsored by: InterSystems Whitepaper on leveraging normalized real-world patient data to streamline clinical trials, reduce delays and lower costs. Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. BioBasics: Biotech For The Non-Scientist May 8-9, 2019 | New York, NY Drug Development Immersion May 16-17, 2019 | Boston, MA 2019 BIO International Convention June 3-6, 2019 | Philadelphia, PA FierceBiotech Executive Breakfast at BIO 2019 – Getting Real: The Changing Tide on Real-World Evidence in Drug Development June 5, 2019 | Philadelphia, PA Medical Sensors Design Conference June 25, 2019 | McEnery Convention Center | San Jose, CA Sensors Expo & Conference June 25-27, 2019 | McEnery Convention Center | San Jose, CA Drug Development Boot Camp® 2019 November 20-21, 2019 | Boston, MA | Register and start preparing Today! | 